Gareth Morgan, MD, FRCP, FRCPath, PhD from the UAMS Myeloma Institute, Little Rock, AR provides an overview of his talk on ‘Treatment strategies at first relapse’ held at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Prof. Morgan discusses why there are many trials and data sets available looking at first relapse in myeloma and the evidence that is available for making decisions. Treatment options include revlimid and dexamethasone, the proteasome inhibitors bortezomib (velcade), carfilzomib and ixazomib, as well as the monoclonal antibodies elotuzumab and daratumumab. According to Prof. Morgan, the triplet combinations on a backbone of velcade or revlimid work best but the question is how to decide which combination to use. He outlines the various characteristics of the drugs and how this might help make a decision.